Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
Insulet (PODD) Enhances Omnipod 5 System with New Target Glucose Option
08.06.2026 03:44
Insulet Corporation (NASDAQ:PODD) is one of the oversold stocks to buy right now. On June 3, Insulet launched significant enhancements to its Omnipod 5 Automated Insulin Delivery/AID System in the US, featuring a new 100 mg/dL Target Glucose option. This update allows for greater personalization and improved glycemic control, enabling users to increase their time […]
Baron Discovery Fund Q1 2026: Who Moved The Needle
08.06.2026 01:35
Baron Discovery Fund declined 10.65% in Q1 2026, trailing its benchmark due to software headwinds. Read the full analysis for more details.
Is Omnipod 5’s Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)?
05.06.2026 08:15
In early June 2026, Insulet began rolling out FDA-cleared algorithm enhancements to its Omnipod 5 Automated Insulin Delivery System in the U.S., adding a 100 mg/dL target option and new compatibility with Abbott’s Libre 3 Plus sensor via over-the-air updates and newly shipped Pods. This combination of tighter glucose personalization, improved automated mode performance, and broader sensor choice strengthens Omnipod 5’s appeal for both patients and clinicians even as the company manages...
Cardiac Monitoring & Rhythm Management Devices Market by Type, Application, End User - Global Forecast to 2031
05.06.2026 08:02
The global cardiac monitoring and cardiac rhythm management devices market is poised for significant growth, projected to reach USD 37.88 billion by 2031, up from USD 27.90 billion in 2026, with a CAGR of 6.3%. Rising awareness and early cardiovascular disease detection drive the demand for these devices, although data security concerns in remote monitoring may challenge adoption. Implantable cardioverter defibrillators dominate the market with continuous protection against cardiac arrest. Home
Jim Cramer Says “No One Disputes the Science and Commercial Smarts of Abbott”
04.06.2026 10:58
Abbott Laboratories (NYSE:ABT) was among the stocks Jim Cramer talked about as he discussed the recent rally in several AI-related stocks. Cramer mentioned the company during the episode and stated: Now, let’s talk about some legendary growth companies and what’s happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and […]
Assessing Abbott Laboratories (ABT) Valuation After New Diabetes Sensor And Cancer Screening Tailwinds
04.06.2026 00:17
Abbott Laboratories (ABT) is back in focus after it expanded its collaboration with MiniMed on dual glucose ketone sensors and received fresh support from the American Cancer Society for its Cologuard colorectal cancer screening tests. See our latest analysis for Abbott Laboratories. Even with supportive news on diabetes sensors and cancer screening, Abbott’s recent share price return tells a different story, with the stock down about 22% over 90 days and its 1-year total shareholder return...
How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment Story
03.06.2026 01:08
Abbott Laboratories currently has no change to its price target, with recent updates leaving existing estimates in place. In this article, you will see what this stable price target may mean for your view on the stock today and how to keep track of shifts as the analyst narrative evolves. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Abbott Laboratories. Do your thoughts align with the Bull or Bear Analysts? Perhaps you...
How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment Story
03.06.2026 01:08
Abbott Laboratories currently has no change to its price target, with recent updates leaving existing estimates in place. In this article, you will see what this stable price target may mean for your view on the stock today and how to keep track of shifts as the analyst narrative evolves. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Abbott Laboratories. Do your thoughts align with the Bull or Bear Analysts? Perhaps you...
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
29.05.2026 13:15
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
29.05.2026 13:00
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Wolfe Research cuts Boston Scientific rating as key growth drivers falter
29.05.2026 12:47
Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.
Is Abbott Laboratories Stock Underperforming the Dow?
29.05.2026 11:30
Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.
Abbott obtains CE mark for duo of glucose-ketone monitors
28.05.2026 11:20
The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.
InMode: My Pick For A Major Turnaround In 2026 And 2027
28.05.2026 09:37
Discover why InMode Ltd. looks undervalued: strong free cash flow, buybacks, and global growth catalystsâget the latest outlook and act now. Click for more on INMD.
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
27.05.2026 11:01
Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC. Both tests are used at a three-year interval.
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
22.05.2026 14:33
MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
22.05.2026 12:55
Carillon Tower Advisers, an investment management company, released its first-quarter 2026 investor letter for the “Carillon Eagle Growth & Income Fund”. A copy of the letter is available to download here. The first quarter of 2026 was volatile due to market shifts, including increased geopolitical risk and inflation fears from rising energy prices. The S&P declined […]
Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
22.05.2026 12:46
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]
Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
22.05.2026 07:15
Abbott Laboratories (NYSE:ABT) is expanding its presence in health tech with new diagnostics and wearable products, including the Lingo biomarker monitoring device. The company is also increasing R&D activity in cardiovascular diagnostics, aiming to broaden its role in earlier detection and ongoing monitoring of heart related conditions. These product moves come as attention on Abbott has recently centered on earnings, insider activity, and the Exact Sciences acquisition rather than its...
Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer
21.05.2026 13:00
The global Paroxysmal Supraventricular Tachycardia (PSVT) market is set for significant growth, driven by advancements in diagnostics and treatment, and rising cardiovascular awareness. Key factors include a surge in cardiovascular diseases, especially in the aging population, and increased use of minimally invasive techniques like catheter ablation. Emerging economies present ample opportunities, supported by improving healthcare infrastructure and preventive healthcare focus. Challenges persis